Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis
Cancer Reports · 2024
DOI: 10.1002/cnr2.2054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Moayed Ibrahim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Janus Kinase 2, Primary Myelofibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carol Lavin Bernick Faculty Grant Program at Tulane University School of Medicine.
Abstract (Originalsprache)
Background
It has been described in mice models that myeloproliferative neoplasm (MPN) with JAK2‐V617F mutation has an increased expression of programmed death‐ligand 1 (PD‐L1) in megakaryocytes leading to cancer immune evasion by inhibiting the T‐lymphocytes.
Aims
To quantify and compare the PD‐L1 expression on bone marrow (BM) of patients with MPN JAK2 positive, negative, and normal controls.
Methods
We collected BM of patients with MPN JAK2 positive, negative and normal controls from 1990 to 2019. We also created a scoring system to quantify PD‐L1 expression in megakaryocytes.
Results
We obtained 14 BM with JAK2 positive PMF, 5 JAK2 negative PMF, and 10 patients with normal BM biopsies. PD‐L1 expression was higher in the JAK2 positive group compared with the control group with a score of 212.6 versus 121.1 ( t ‐value 2.05, p ‐value 0.025). In addition, the score was higher in the PMF group regardless of JAK2 mutational status when compared with the control group with score of 205.9 versus 121.1 ( t ‐value 2.12, p ‐value 0.021). There was no difference in the PD‐L1 score between the JAK2 negative versus the control group 187.2 versus 121.1 ( t ‐value 1.02, p ‐value 0.162).
Conclusion
These findings suggest that PMF patients with a JAK2 mutation have a higher PD‐L1 expression in megakaryocytes compared with the control group. We postulate that the combination of checkpoint and JAK2 inhibitors may be an active treatment option in JAK2 mutated PMF given the higher PD‐L1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.
- Delta Pathology Group, Shreveport, Louisiana, USA.
- Pathology Department, Tulane University, New Orleans, Louisiana, USA.
- Hematology and Bone Marrow Transplant, University of California Davis, Sacramento, California, USA.
ORCID-Profile: Moayed Ibrahim, Francisco Socola
Förderung
- Carol Lavin Bernick Faculty Grant Program at Tulane University School of Medicine
Zitieren
APA
Ibrahim, M., Murphree, C., Patel, K., Mastrodomenico, M., Saba, N. S., Safah, H., Schmid, J., & Socola, F. (2024). Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis. Cancer Reports. https://doi.org/10.1002/cnr2.2054
Vancouver
Ibrahim M, Murphree C, Patel K, Mastrodomenico M, Saba NS, Safah H, et al. Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis. Cancer Reports. 2024. doi:10.1002/cnr2.2054
BibTeX
@article{Ibrahim2024,
author = {Ibrahim, Moayed and Murphree, Catherine and Patel, Kirtesh and Mastrodomenico, Matthew and Saba, Nakhle S and Safah, Hana and Schmid, Janet and Socola, Francisco},
title = {Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2054}
}
EUVIMED